中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.024 seconds)

    Benzimidazole Derivatives As PI3 Kinase Inhibitors
    2.
    发明申请
    Benzimidazole Derivatives As PI3 Kinase Inhibitors 有权
    苯并咪唑衍生物作为PI3激酶抑制剂

    公开(公告)号：US20150246889A1

    公开(公告)日：2015-09-03

    申请号：US14712991

    申请日：2015-05-15

    Applicant: GlaxoSmithKline LLC

    Inventor： Junya Qu ,  Ralph A. Rivero ,  Robert Sanchez ,  Rosanna Tedesco

    IPC: C07D235/08

    CPC classification number: A61K31/5377 ,  A61K31/337 ,  C07D235/08 ,  C07D235/10 ,  C07D235/24 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D409/10 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/10

    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.

    Abstract translation: 本发明涉及苯并咪唑衍生物用于调节的用途，特别是抑制磷酸肌醇3'OH激酶家族（以下称为PI3激酶），适当的是PI3Kα，PI3Kδ，PI3K＆bgr和/或PI3Kγ的活性或功能。 合适地，本发明涉及苯并咪唑在治疗一种或多种疾病状态中的用途，所述疾病状态选自：自身免疫性疾病，炎性疾病，心血管疾病，神经变性疾病，过敏，哮喘，胰腺炎，多器官衰竭，肾脏疾病，血小板聚集， 癌症，精子活力，移植排斥反应，移植物排斥反应和肺损伤。 更合适地，本发明涉及PI3K＆bgr; 用于治疗癌症的选择性苯并咪唑化合物。

    Benzimidazole Derivatives As PI3 Kinase Inhibitors
    7.
    发明申请
    Benzimidazole Derivatives As PI3 Kinase Inhibitors 有权
    苯并咪唑衍生物作为PI3激酶抑制剂

    公开(公告)号：US20140142321A1

    公开(公告)日：2014-05-22

    申请号：US14164414

    申请日：2014-01-27

    Applicant: GlaxoSmithKline LLC

    Inventor： Junya Qu ,  Ralph A. Rivero ,  Robert Sanchez ,  Rosanna Tedesco

    IPC: C07D235/08

    CPC classification number: A61K31/5377 ,  A61K31/337 ,  C07D235/08 ,  C07D235/10 ,  C07D235/24 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D409/10 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/10

    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.

    Abstract translation: 本发明涉及苯并咪唑衍生物用于调节的用途，特别是抑制磷酸肌醇3'OH激酶家族（以下称为PI3激酶），适当的是PI3Kα，PI3Kδ，PI3K＆bgr和/或PI3Kγ的活性或功能。 合适地，本发明涉及苯并咪唑在治疗一种或多种疾病状态中的用途，所述疾病状态选自：自身免疫性疾病，炎性疾病，心血管疾病，神经变性疾病，过敏，哮喘，胰腺炎，多器官衰竭，肾脏疾病，血小板聚集， 癌症，精子活力，移植排斥反应，移植物排斥反应和肺损伤。 更合适地，本发明涉及PI3K＆bgr; 用于治疗癌症的选择性苯并咪唑化合物。

    Benzimidazole derivatives as PI3 kinase inhibitors
    8.
    发明授权
    Benzimidazole derivatives as PI3 kinase inhibitors 有权
    苯并咪唑衍生物作为PI3激酶抑制剂

    公开(公告)号：US08674090B2

    公开(公告)日：2014-03-18

    申请号：US14031136

    申请日：2013-09-19

    Applicant: GlaxoSmithKline LLC

    Inventor： Junya Qu ,  Ralph A. Rivero ,  Robert Sanchez ,  Rosanna Tedesco

    IPC: C07D413/04 ,  C07D413/10

    CPC classification number: A61K31/5377 ,  A61K31/337 ,  C07D235/08 ,  C07D235/10 ,  C07D235/24 ,  C07D401/10 ,  C07D403/04 ,  C07D403/10 ,  C07D405/04 ,  C07D405/10 ,  C07D409/10 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/10

    Abstract: This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of benzimidazoles in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective benzimidazoles compounds for treating cancer.

    Abstract translation: 本发明涉及苯并咪唑衍生物用于调节，特别是抑制磷酸肌醇3'OH激酶家族（以下称为PI3激酶），适当地PI3Kα，PI3Kdelta，PI3Kβ和/或PI3Kgamma的活性或功能的用途。 合适地，本发明涉及苯并咪唑在治疗一种或多种疾病状态中的用途，所述疾病状态选自：自身免疫性疾病，炎性疾病，心血管疾病，神经变性疾病，过敏，哮喘，胰腺炎，多器官衰竭，肾脏疾病，血小板聚集， 癌症，精子活力，移植排斥反应，移植物排斥反应和肺损伤。 更合适地，本发明涉及用于治疗癌症的PI3Kβ选择性苯并咪唑化合物。

Patent Agency Ranking